Basal insulin evolution: from simple to more complex
AbstractInsulin therapy is the main component of the type 1 diabetes treatment. Since the discovery of insulin in 1920's and to the present day the improvement of insulin has been an ongoing process. In a century insulin therapy has gone from insulin extracted from cattle pancreas to the second-generation basal insulin analogues which is the closest thing to the physiological insulin secretion. The article presents a review of basal insulin preparations evolution. The main tendency consists in the prolonging of insulin action. The use of the second-generation basal insulin preparations allows achieving diabetes compensation and reducing the risk of hypoglycemia
Keywords:insulin therapy, basal insulin, hypoglycemia, pharmacodynamics, pharmacokinetics, long-acting insulin of the second generation
Funding. The study had no sponsor support.
Conflict of interests. The authors declare no conflict of interests.
For citation: Okminyan G.F., Latyshev O.Yu., Kiseleva E.V., Kasatkina E.P., Samsonova L.N. Basal insulin evolution: from simple to more complex. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2021; 10 (1): 18-25. DOI: https://doi.org/10.33029/2304-9529-2021-10-1-18-25 (in Russian)
References
1. DiMeglio L.A., Acerini C.L., Codner E., Craig M.E., Hofer S.E., Pillay K., et al. ISPAD Clinical Practice Consensus Guidelines 2018: Glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. Pediatr Diabetes. 2018; 19 (suppl 27): 105-14. DOI: https://doi.org/10.1111/pedi.12737 PMID: 30058221.
2. Battelino T., Danne T., Bergenstal R.M., Amiel S.A., Beck R., Biester T., et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range. Diabetes Care. 2019; 42 (8): 1593-603. DOI: https://doi.org/10.2337/dci19-0028 PMID: 31177185; PMCID: PMC 6973648.
3. American Diabetes Association. Glycemic Targets: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020; 43 (suppl 1): S 6676. DOI: https://doi.org/10.2337/dc20-S006 PMID: 31862749.
4. Standards of specialized diabetes care. In: I.I. Dedov, M.V. Shestakova, A. Yu. Mayorov (eds). 9th ed. Sakharniy diabet [Diabetes Mellitus]. 2019; 22 (1S 1): 1-144. DOI: https://doi.org/10.14341/DM221S1 (in Russian)
5. Hegele R.A., Maltman G.M. Insulin’s centenary: the birth of an idea. Lancet Diabetes Endocrinol. 2020; 8 (12): 971-7. DOI: https://doi.org/10.1016/S2213-8587(20)30337-5 PMID: 33129375.
6. Garber A.J. Will the next generation of basal insulins offer clinical advantages? Diabetes Obes Metab. 2014; 16 (6): 483-91. DOI: https://doi.org/10.1111/dom.12219 PMID: 24118819.
7. Bolli G.B., Andreoli A.M., Lucidi P. Optimizing the replacement of basal insulin in type 1 diabetes mellitus: no longer an elusive goal in the post-NPH era. Diabetes Technol Ther. 2011; 13 (suppl 1): S 43-52. DOI: https://doi.org/10.1089/dia.2011.0039 PMID: 21668336.[11]
8. Hirsch I.B., Juneja R., Beals J.M., Antalis C.J., Wright E.E. The Evolution of insulin and how it informs therapy and treatment choices. Endocr Rev. 2020; 41 (5): 733-55. DOI: https://doi.org/10.1210/endrev/bnaa015
9. Pettus J., Santos Cavaiola T., Tamborlane W.V., Edelman S. The past, present, and future of basal insulins. Diabetes Metab Res Rev. 2016; 32 (6): 478-96. DOI: https://doi.org/10.1002/dmrr.2763 PMID: 26509843.
10. Cheng A.Y.Y., Patel D.K., Reid T.S., Wyne K. Differentiating basal insulin preparations: understanding how they work explains why they are different. Adv Ther. 2019; 36 (5): 1018-30. DOI: https://doi.org/10.1007/s12325-019-00925-6
11. Heise T., Mathieu C. Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diabetes Obes Metab. 2017; 19 (1): 3-12. DOI: https://doi.org/10.1111/dom.12782 PMID: 27593206; PMCID: PMC 5215074.
12. Home P.D., Bergenstal R.M., Bolli G.B., Ziemen M., Rojeski M., Es-pinasse M., et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care. 2015; 38 (12): 2217-25. DOI: https://doi.org/10.2337/dc15-0249 PMID: 26084341.
13. Anderson J.E. An evolutionary perspective on basal insulin in diabetes treatment: innovations in insulin: insulin glargine U-300. J Fam Pract. 2016; 65 (10 suppl): S 23-8. PMID: 27846339.
14. Danne T., Matsuhisa M., Sussebach C., et al. Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: a meta-analysis of 6-month phase 3 clinical trials. Diabetes Obes Metab. 2020; 22 (10): 1880-5. DOI: https://doi.org/10.1111/dom.14109
15. Bergenstal R.M., Bailey T.S., Rodbard D., Ziemen M., Guo H., Mue-hlen-Bartmer I., et al. Comparison of insulin glargine 300 units/mL and 100 units/mL in adults with type 1 diabetes: continuous glucose monitoring profiles and variability using morning or evening injections. Diabetes Care. 2017; 40 (4): 554-60. DOI: https://doi.org/10.2337/dc16-0684 PMID: 28115474.
16. Subramanian S., Baidal D., Skyler J.S., Hirsch I.B. The management of type 1 diabetes. 2016 Nov 16. In: Endotext [Internet]. K.R. Feingold, B. Anawalt, A. Boyce, G. Chrousos, W.W. de Herder, K. Dungan, et al. (eds). South Dartmouth, MA: MDText.com, 2000. PMID: 25905338.